Comparison between LEAP India IPO and Molbio Diagnostics IPO.
LEAP India IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Molbio Diagnostics IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of LEAP India IPO is up to ₹2,400.00 Cr whereas the issue size of the Molbio Diagnostics IPO is up to ₹0.00 Cr. The final issue price of LEAP India IPO is and of Molbio Diagnostics IPO is .
| LEAP India IPO | Molbio Diagnostics IPO | |
|---|---|---|
| Face Value | ₹1 per share | ₹1 per share |
| Issue Price (Lower) | ||
| Issue Price (Upper) | ||
| Issue Price (Final) | ||
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | ||
| Fresh Issue Size | 0 shares | 0 shares |
| Fresh Issue Size (Amount) | up to ₹400.00 Cr | up to ₹200.00 Cr |
| OFS Issue Size | 0 shares | 1,25,56,000 shares |
| OFS Issue Size (Amount) | up to ₹2,000.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 0 shares | 0 shares |
| Issue Size Total (Amount) | up to ₹2,400.00 Cr | up to ₹0.00 Cr |
LEAP India IPO opens on , while Molbio Diagnostics IPO opens on . The closing date of LEAP India IPO and Molbio Diagnostics IPO is , and , respectively.
LEAP India IPO P/E ratio is , as compared to Molbio Diagnostics IPO P/E ratio of .
| LEAP India IPO | Molbio Diagnostics IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)LEAP India Ltd.'s revenue increased by 30% and profit after tax (PAT) rose by 1% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated)Molbio Diagnostics Ltd.'s revenue increased by 22% and profit after tax (PAT) rose by 66% between the financial year ending with March 31, 2025 and March 31, 2024.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 95.62 | 46.65 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 4.60% | 16.20% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 18.01% | 20.98% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.87 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹12.29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 4.09% | 15.23% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the LEAP India IPO Retail Individual Investors (RII) are offered 0 shares while in Molbio Diagnostics IPO retail investors are offered 0 shares. Qualified Institutional Buyers (QIB) are offered 0 shares in LEAP India IPO and 0 shares in Molbio Diagnostics IPO.
| LEAP India IPO | Molbio Diagnostics IPO | |
|---|---|---|
| Anchor Investor Reservation | 0 shares | 0 shares |
| Market Maker Reservation | 0 shares | 0 shares |
| QIB | 0 shares | 0 shares |
| NII | 0 shares | 0 shares |
| RII | 0 shares | 0 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 0 shares | 0 shares |
LEAP India IPO subscribed in total, whereas Molbio Diagnostics IPO subscribed .
